Jefferies says September lung data can offset AstraZeneca trial failure - Proactive Investors
... failure of a separate heart trial. The bank has reiterated its buy rating and 17,500p price target, implying 41% upside from the current 12,380p ...
Read the original at Proactive Investors ↗
- Topics
- Markets & InvestmentBanking & Finance
- Tracked via
- “AI Falures”